Alnylam Pharmaceuticals Stock Rating Upgraded by Needham & Company (ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by research analysts at Needham & Company to a “positive” rating in a report released on Monday, Analyst Ratings.Net reports. The firm currently has a $65.00 target price on the stock. Needham & Company’s price objective indicates a potential upside of 13.59% from the stock’s previous close.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 10.30% on Monday, hitting $63.1201. 1,424,330 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a one year low of $14.88 and a one year high of $58.55. The stock’s 50-day moving average is $51.99 and its 200-day moving average is $35.36. The company’s market cap is $3.974 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.29) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.06. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.99 million. During the same quarter last year, the company posted ($0.25) earnings per share. Alnylam Pharmaceuticals’s revenue was down 58.4% compared to the same quarter last year. On average, analysts predict that Alnylam Pharmaceuticals will post $-1.25 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Leerink Swann raised their price target on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) to $80.00 in a research note to investors on Monday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note to investors on Friday, August 16th. They now have a $51.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from an “outperform” rating to a “neutral” rating in a research note to investors on Saturday, July 20th. They now have a $45.00 price target on the stock.
Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $59.25.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 58,947 shares of Alnylam Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $55.50, for a total transaction of $3,271,558.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.